Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
Open Access
- 1 January 2012
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 10 (1) , 66
- https://doi.org/10.1186/1477-7525-10-66
Abstract
In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients. This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial’s 12 week treatment induction period.Keywords
This publication has 45 references indexed in Scilit:
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- A systematic review of health-related quality of life in cutaneous melanomaAnnals of Oncology, 2009
- Cutaneous melanoma in the elderlyMelanoma Research, 2009
- Current management of metastatic melanomaAmerican Journal of Health-System Pharmacy, 2008
- Quality of life research within the EORTC—the EORTC QLQ-C30European Journal Of Cancer, 2002
- Cognitive Function and Quality of Life in Interferon Therapy for MelanomaClinical Nursing Research, 2000
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- The prevalence of psychiatric disorders among cancer patientsJAMA, 1983